Carlsmed Beats Estimates, Raises Sales Guidance
The personalized spine surgery company reported narrower quarterly losses and stronger sales than analysts expected, and lifted its full-year outlook.
Updated on Nov. 11, 2026 in Healthcare

Carlsmed reported third-quarter results that beat analyst estimates, with a quarterly loss of 34 cents per share against a consensus estimate of 40 cents and sales of $21.554 million against $19.154 million expected. The company also raised its FY2026 sales guidance to $78.000 million-$80.000 million from $74.000 million-$78.000 million.
Why it matters
The results show revenue growth of 65% and a surgeon user base up more than 60% over the prior year, signaling demand for its personalized surgery platform. Shares rose 19.5% to $17.58 on Wednesday as several analysts raised price targets.
Quarterly sales rose 65% year over year to $21.554 million, beating the $19.154 million consensus, while the per-share loss narrowed to 34 cents from a 40-cent estimate. The source does not disclose the company's path to breakeven or its operating cash flow.
The players
Carlsmed
Carlsmed is a medical device company that offers personalized spine surgery technology, including its aprevo lumbar spine fusion platform.
Mike Cordonnier
Mike Cordonnier is the chief executive of Carlsmed, who is cited in the company's results announcement.
The details
Carlsmed posted the results on Tuesday, and its shares climbed the following day. The company said it broadened its personalized surgery platform, strengthened its leadership team, and secured new inpatient CMS reimbursement for its aprevo lumbar spine fusion procedure.
Timeline
Tuesday, November 10, 2026: Carlsmed reports third-quarter results.
Wednesday, November 11, 2026: Shares gain 19.5% to trade at $17.58.
FY2026: Sales guidance raised to $78.000 million-$80.000 million.
Healthcare Reimbursement Pathway
Carlsmed's newly secured inpatient CMS reimbursement for its aprevo lumbar spine fusion procedure is the mechanism tied to the company's raised sales outlook and expanding surgeon base. The company describes these accomplishments as reinforcing its foundation for sustainable, profitable long-term growth into 2027.
Surgeons and hospitals gaining inpatient reimbursement for the aprevo procedure may see broader access to personalized spine surgery options. Patients are not directly affected by the earnings results themselves, and the source does not address changes to patient costs.
The takeaway
Growth in surgeon adoption and reimbursement coverage can translate into higher revenue for specialized medical device makers. Investors should watch whether raised guidance holds through the next reporting period.
Further reading
For more on how medical device companies are navigating reimbursement and growth, explore Healthcare coverage.






